載入...
ACTR-10. PHASE 0 TRIAL OF CERITINIB IN BRAIN METASTASES AND RECURRENT GLIOBLASTOMA
BACKGROUND: Ceritinib is an orally bioavailable, small molecule inhibitor for ALK/IGFR1/FAK, which are highly expressed in glioblastoma and brain metastases. Preclinical and clinical reports suggest ceritinib activity in central nervous system (CNS) malignancies, yet there is no direct evidence in p...
Na minha lista:
| 發表在: | Neuro Oncol |
|---|---|
| Main Authors: | , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Oxford University Press
2019
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6847618/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.053 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|